Abstract
Previously reported results have shown that the inhibitory effect of fluoxetine on escape behavior, interpreted as a panicolytic-like effect, is blocked by pretreatment with either the opioid receptor antagonist naloxone or the 5-HT1A receptor (5-HT1A-R) antagonist WAY100635 via injection into the dorsal periaqueductal gray matter (dPAG). Additionally, reported evidence indicates that the μ-opioid receptor (MOR) interacts with the 5-HT1A-R in the dPAG. In the present work, pretreatment of the dPAG with the selective MOR blocker CTOP antagonized the anti-escape effect of chronic fluoxetine (10 mg/kg, i.p., daily, for 21 days), as measured in the elevated T-maze (ETM) test, indicating mediation of this effect by the MOR. In addition, the combined administration of sub-effective doses of the selective MOR agonist DAMGO (intra-dPAG) and sub-effective doses of chronic as well as subchronic (7 days) fluoxetine increased avoidance and escape latencies, suggesting that the activation of MORs may facilitate and accelerate the effects of fluoxetine. The current observation that MORs located in the dPAG mediate the anti-escape effect of fluoxetine may open new perspectives for the development of more efficient and fast-acting panic-allevi...Continue Reading
References
Jan 1, 1969·Journal of Neurosurgery·B S NasholdD G Slaughter
Jul 28, 1995·Psychiatry Research·F JenckJ R Martin
Sep 1, 1994·Trends in Neurosciences·R Bandler, M T Shipley
Feb 1, 1993·Pharmacology, Biochemistry, and Behavior·D TreitC Royan
Aug 1, 1995·Psychopharmacology·V MottaM L Brandão
Jan 12, 1999·Neuroscience and Biobehavioral Reviews·F G GraeffH Zangrossi
Jan 16, 1999·Brain Research·J M de GandariasL Casis
Apr 15, 2000·Pharmacology, Biochemistry, and Behavior·R C TeixeiraF G Graeff
Oct 6, 2001·Neuropharmacology·K KishimotoN Akaike
Dec 26, 2001·Neuropharmacology·G C D EichenbergerN C Coimbra
Jan 22, 2002·Neuroscience and Biobehavioral Reviews·H ZangrossiF G Graeff
Jan 22, 2002·Neuroscience and Biobehavioral Reviews·L C SchenbergL C Vargas
Jun 5, 2002·European Journal of Pharmacology·Catherine VilpouxJean Costentin
Aug 2, 2003·European Journal of Pharmacology·Janaina M ZanoveliHélio Zangrossi
Nov 1, 2005·Psychopharmacology·Valquíria Camin de BortoliHélio Zangrossi
Jun 21, 2006·NeuroImage·Adam J SchwarzAngelo Bifone
Feb 23, 2007·Neuropharmacology·Janaina Menezes ZanoveliHélio Zangrossi
Apr 3, 2007·Anais Da Academia Brasileira De Ciências·Simone H PinheiroFrederico G Graeff
Mar 14, 2009·Neural Plasticity·Cristina Marta Del-Ben, Frederico Guilherme Graeff
Jun 10, 2010·Central Nervous System Agents in Medicinal Chemistry·Frederico G Graeff, Hélio Zangrossi
Sep 21, 2010·Neuropharmacology·Paula Shimene de Melo YamashitaHelio Zangrossi
Jan 1, 1991·Journal of Psychopharmacology·J F Deakin, F G Graeff
Apr 16, 2013·Cell and Tissue Research·Fabrício A MoreiraFrederico G Graeff
Mar 25, 2014·Neuroscience and Biobehavioral Reviews·Hélio Zangrossi, Frederico G Graeff
Mar 3, 2015·Synapse·Rafael Carvalho Almada, Norberto Cysne Coimbra
Jul 5, 2015·Neuroscience·R C AlmadaN C Coimbra
Jul 25, 2015·Behavioural Brain Research·Farhad UllahNorberto Cysne Coimbra
Citations
Nov 8, 2015·Behavioural Brain Research·Audrey Francisco BiagioniNorberto Cysne Coimbra
Dec 26, 2016·Peptides·Richard J Bodnar
Nov 9, 2018·Journal of Psychopharmacology·Fabrício CalvoNorberto Cysne Coimbra
Oct 19, 2016·Synapse·Renato Leonardo de FreitasNorberto Cysne Coimbra
Jan 22, 2019·Journal of Psychopharmacology·Fabrício CalvoNorberto Cysne Coimbra
Feb 12, 2017·Brain Structure & Function·S ChomettonP Y Risold
Jan 10, 2019·Biological Psychiatry·Andrew M Novick, David A Ross